Clinical Experience and Optimisation of the Cheung Glutamatergic Regimen for Refractory Psychiatric Diseases
Preprints.org November 28, 2025 preprint DOI: 10.20944/preprints202511.2246.v1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Interventions | CYP2D6 inhibitor piracetam |
| Topics | Anxiety |
| Keywords | Glutamatergic Regimen Riluzole Refractory planetary science Clinical pharmacology Piracetam Pharmacogenomics Pharmacokinetics Lamotrigine Anesthesia Intensive care medicine Depression economics Mood stabilizer Glutamate receptor Fluoxetine |
| Citations | 6 |
| Key findings | The Cheung glutamatergic regimen can produce rapid recoveries in refractory mood and anxiety disorders, but careful pharmacokinetic management is essential to avoid toxicity. |
Abstract
Intravenous ketamine has transformed the care of refractory mood and anxiety disorders, yet its cost and clinical complexity keep many patients on the sidelines. The Cheung glutamatergic regimen tries to bring the same rapid-acting biology to the outpatient clinic with nothing more exotic than pharmacy-shelf capsules. The protocol pairs dextromethorphan, whose σ-1/NMDA activity mirrors ketamine’s, with a CYP2D6 inhibitor to slow its metabolism, then adds piracetam to drive AMPA throughput and oral l-glutamine to bolster the glutamate pool. Case reports and small open series describe sudden, occasionally dramatic recoveries in depression, PTSD, chronic pain and functional somatic syndromes. Those early successes, however, arrive only when the pharmacokinetics are handled with care. The CYP2D6 blocker that keeps dextromethorphan in circulation can just as easily push it—or a co-prescribed psychotropic—into toxic territory.